Literature DB >> 28155173

Impact of acromegaly treatment on cardiovascular complications.

Adriana G Ioachimescu1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28155173     DOI： 10.1007/s12020-016-1218-9

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  21 in total

1.  The treatment with growth hormone receptor antagonist in acromegaly: effect on vascular structure and function in patients resistant to somatostatin analogues.

Authors:  M C De Martino; R S Auriemma; G Brevetti; G Vitale; V Schiano; M Galdiero; L Grasso; G Lombardi; A Colao; R Pivonello
Journal:  J Endocrinol Invest       Date:  2010-07-01       Impact factor: 4.256

2.  Low Frequency of Cardiomyopathy Using Cardiac Magnetic Resonance Imaging in an Acromegaly Contemporary Cohort.

Authors:  Cintia Marques dos Santos Silva; Ilan Gottlieb; Isabela Volschan; Leandro Kasuki; Leila Warszawski; Giovanna Aparecida Balarini Lima; Sergio Salles Xavier; Roberto Coury Pedrosa; Leonardo Vieira Neto; Mônica R Gadelha
Journal:  J Clin Endocrinol Metab       Date:  2015-10-02       Impact factor: 5.958

3.  The metabolic profile in active acromegaly is gender-specific.

Authors:  A Ciresi; M C Amato; R Pivonello; E Nazzari; L F Grasso; F Minuto; D Ferone; A Colao; C Giordano
Journal:  J Clin Endocrinol Metab       Date:  2012-11-15       Impact factor: 5.958

4.  Comparison of the effects of primary somatostatin analogue therapy and pituitary adenomectomy on survival in patients with acromegaly: a retrospective cohort study.

Authors:  Fausto Bogazzi; Annamaria Colao; Giuseppe Rossi; Martina Lombardi; Claudio Urbani; Chiara Sardella; Aldo Iannelli; Ilaria Scattina; Luca Manetti; Simone Del Sarto; Rosario Pivonello; Ludovica Francesca Stella Grasso; Isabella Lupi; Renata Simona Auriemma; Gaetano Lombardi; Enio Martino
Journal:  Eur J Endocrinol       Date:  2013-08-28       Impact factor: 6.664

5.  Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide.

Authors:  Annamaria Colao; Paolo Marzullo; Alberto Cuocolo; Letizia Spinelli; Rosario Pivonello; Domenico Bonaduce; Marco Salvatore; Gaetano Lombardi
Journal:  Clin Endocrinol (Oxf)       Date:  2003-02       Impact factor: 3.478

6.  Cardiac risk in patients with treatment naïve, first-line medically controlled and first-line surgically cured acromegaly in comparison to matched data from the general population.

Authors:  C Berg; S Petersenn; M Walensi; S Möhlenkamp; M Bauer; N Lehmann; U Roggenbuck; S Moebus; M Broecker-Preuss; I E Sandalcioglu; D Stolke; U Sure; K H Joeckel; R Erbel; D Führer; K Mann
Journal:  Exp Clin Endocrinol Diabetes       Date:  2013-01-21       Impact factor: 2.949

7.  Mortality in acromegaly: a 20-year follow-up study.

Authors:  Elina Ritvonen; Eliisa Löyttyniemi; Pia Jaatinen; Tapani Ebeling; Leena Moilanen; Pirjo Nuutila; Ritva Kauppinen-Mäkelin; Camilla Schalin-Jäntti
Journal:  Endocr Relat Cancer       Date:  2016-05-16       Impact factor: 5.678

8.  Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study.

Authors:  Jakob Dal; Ulla Feldt-Rasmussen; Marianne Andersen; Lars Ø Kristensen; Peter Laurberg; Lars Pedersen; Olaf M Dekkers; Henrik Toft Sørensen; Jens Otto L Jørgensen
Journal:  Eur J Endocrinol       Date:  2016-06-08       Impact factor: 6.664

Review 9.  Current and Emerging Aspects of Diabetes Mellitus in Acromegaly.

Authors:  Stefano Frara; Filippo Maffezzoni; Gherardo Mazziotti; Andrea Giustina
Journal:  Trends Endocrinol Metab       Date:  2016-05-24       Impact factor: 12.015

10.  Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study.

Authors:  Emmanuelle Kuhn; Luigi Maione; Amir Bouchachi; Myriam Rozière; Sylvie Salenave; Sylvie Brailly-Tabard; Jacques Young; Peter Kamenicky; Patrick Assayag; Philippe Chanson
Journal:  Eur J Endocrinol       Date:  2015-11       Impact factor: 6.664
View more
  1 in total

Review 1.  Effects of somatostatin analog treatment on cardiovascular parameters in patients with acromegaly: A systematic review.

Authors:  Maryam Heidarpour; Davood Shafie; Ashraf Aminorroaya; Nizal Sarrafzadegan; Ziba Farajzadegan; Rasool Nouri; Arash Najimi; Christina Dimopolou; Gunter Stalla
Journal:  J Res Med Sci       Date:  2019-04-26       Impact factor: 1.852
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.